Flashpoint Therapeutics

United States - Palo Alto, California

• 26/10/2023
• Seed
• $10,000,000

Flashpoint Therapeutics is developing a new class of cancer immunotherapies through rational nanoscale design of therapeutic architecture to optimize anti-tumor immune response.

Across 9 in vivo mouse studies, Flashpoint nanostructures have achieved near curative or curative efficacy using the same therapeutic components that are ineffective in conventional formulations.

Flashpoint leverages 20 years of research from the lab of co-founder Dr. Chad Mirkin -- Professor at Northwestern and Director of the International Institute for Nanomedicine, who has founded 3 public or acquired companies and commercialized over 2,000 products.

Flashpoint will efficiency move development candidates through clinical testing by leveraging established GMP compliant manufacturing capabilities and FDA approved regulatory paths previously developed to support clinical studies based on components of Flashpoint platform.

Flashpoint has assembled an experienced leadership team over core functional areas and is poised to initiate building the company's asset pipeline through partnerships and in-house development.

Related People

Adam MargolinFounder

United States - New York, New York

Strategic and technical data science and biotechnology leader with 10 years of experience building and leading translational and research programs in data science, genetics, oncology, and precision medicine. Proven record building successful and durable programs across 4 institutions, including current executive leadership of a 700-person organization with over $100M annual budget that rose to become the #3 ranked genetics department in the country. Accomplished researcher as evidenced by 28 funded projects, an active publication record, and development of multiple widely used algorithms including one that ranked as the 2nd most influential computational biology algorithm in Google Scholar’s compilation of Classic Papers.

LinkedIn https://www.linkedin.com/in/adam-margolin-332a196/